A cross-sectional study on the Sexual Function of Adult Survivors and their partners 3 and 15 years Post allogeneic Stem Cell Transplantation.

Inclusion criteria:
1) Age ≥ 18 years
2) Time of follow up 2 - 4 years post transplant
3) Ability to read and write in English, French, German, Italian or Dutch
4) No cognitive impairment

Primary objective: To explore patients' and their partners' opinions on their sexual functioning 2 till 4 and 14 till 16 years post Allogeneic HSCT.

Sexual dysfunction has increasingly been recognized as a complication of allogeneic stem cell transplantation with negative impact in their quality of life. The sexual partner might also contribute to sexual dysfunction or to sexual inactivity. Furthermore, patients and their partners have reported to be disappointed by the lack of information, support, and practical strategies provided by health professionals to assist them to cope with the sexual changes they experienced.

Primary objective:
1) To explore patients’ and their partners’ opinions on their sexual functioning 2 till 4 and 14 till 16 years post Allogeneic HSCT.
2) To evaluate if, adequate help or counseling with regard to sexual function between the health care provider and the survivor has taken place.

Inclusion criteria:
- Age ≥ 18 years
- Time of follow up 2 - 4 or 14 - 16 years after transplantation at time of data collection
- Ability to read and write in English, French, German, Italian or Dutch
- No cognitive impairment

*This study is still recruiting*

Non interventional study: Association between uric acid levels and GVHD

PI: Olaf Penack.

It has been demonstrated in preclinical models that uric acid contributes to GVHD. In this prospective study, uric acid levels are assessed of patients undergoing allo-SCT. The uric acid levels will be correlated to clinical outcome.

Primary objective: To assess if uric acid levels are associated with incidence and severity of Acute GVHD

Inclusion criteria:
- First allo-SCT from HLA-matched sibling donors given stem cell grafts (BM or PB)
- Patients with acute leukemia, MDS or lymphoma
- Myeloablative or dose-reduced non-myeloablative conditioning

Current status: 22 sites participating, hoping to collect 400 patients. Currently 390 patients enrolled.

*Please send in your data*

TCWP meetings:
- EBMT Annual Meeting Lisbon: TCWP Session
  Monday, 19th March, 09:00-10:30
  Room: 3C
- EBMT Annual Meeting Lisbon: TCWP Business Meeting
  Tuesday, 20th March, 07:00-09:00
  Room: 5C

TCWP Educational Meeting in Zagreb, Croatia
8th November 2018 - 10th November 2018

All studies from 2017 onwards will be coordinated by the Paris Data Office. The TCWP study coordinator is Alenca Harrington: alenca.harrington@upmc.fr, however studies started before 2017 by the Leiden Office will stay with the previous study coordinator, Stefie van der Werf: S.M.van_der_Werf@lumc.nl

#EBMT18 www.ebmt.org